| |
Mitiglinide
|
Glimepiride
|
|---|
|
n (M/F)
|
15 (10/5)
|
7 (6/1)
|
|
Age, years
|
58.5 ± 11.5
|
65.1 ± 7.5
|
|
BMI, kg/m2
|
24.8 ± 4.0
|
26.3 ± 6.2
|
|
SBP, mmHg
|
137 ± 17
|
132 ± 20
|
|
DBP, mmHg
|
80 ± 7
|
79 ± 11
|
|
Total cholesterol, mmol/L
|
5.38 ± 0.98
|
5.43 ± 1.08
|
|
(mg/dL)
|
(208 ± 38)
|
(210 ± 42)
|
|
Triglycerides, mmol/L
|
1.71 ± 1.14
|
1.89 ± 0.74
|
|
(mg/dL)
|
(152 ± 101)
|
(168 ± 66)
|
|
HDL-C, mmol/L
|
1.39 ± 0.38
|
1.37 ± 0.31
|
|
(mg/dL)
|
(54 ± 15)
|
(53 ± 12)
|
|
Fasting glucose, mmol/L
|
6.88 ± 1.27
|
8.16 ± 1.05
|
|
(mg/dL)
|
(124 ± 23)
|
(147 ± 19)
|
|
2-h postload glucose, mmol/L
|
9.11 ± 1.94
|
11.6 ± 1.77
|
|
(mg/dL)
|
(164 ± 35)
|
(209 ± 32)
|
|
HbA1c(NGSP),%
|
6.80 ± 0.54
|
7.60 ± 0.63
|
|
Fasting IRI, pmol/L
|
52.7 ± 53.4
|
49.3 ± 36.1
|
|
(ng/mL)
|
(7.6 ± 7.7)
|
(7.1 ± 5.2)
|
|
HOMA-R
|
2.55 ± 3.10
|
2.67 ± 2.09
|
|
ISI (Matsuda’s index)
|
7.73 ± 3.16
|
7.68 ± 4.69
|
|
Insulinogenic index
|
0.80 ± 0.61
|
0.42 ± 0.38
|
|
CPR, nmol/L
|
0.59 ± 0.30
|
0.57 ± 0.17
|
|
(ng/mL)
|
(1.79 ± 0.93)
|
(1.72 ± 0.51)
|
|
Proinsulin, pmol/L
|
4.29 ± 4.16
|
4.77 ± 4.04
|
|
PI/I ratio
|
0.10 ± 0.11
|
0.19 ± 0.26
|
- Data are means ± standard deviation.
- BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; IRI, immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; CPR, C-peptide immunoreactivity; PI/I ratio, proinsulin/insulin ratio.
